CPI-0209

Novartis' Fabhalta (iptacopan) demonstrated significant proteinuria reduction in the Phase III APPEAR-C3G trial, meeting its primary endpoint and supporting regulatory submissions.

The T-cell malignancies market is experiencing growth driven by increased incidence, treatment advancements, and strategic biopharma partnerships.

ORIC Pharmaceuticals presented new data on two cancer drug candidates, ORIC-944 and ORIC-613, at the AACR Annual Meeting, showing potential in overcoming therapeutic resistance in cancer. ORIC-944 targets prostate cancer with a promising clinical half-life, while ORIC-613 shows synthetic lethality in TRIM37-high tumor models.